Literature DB >> 1453131

The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I.

A G Johansson1, P Burman, K Westermark, S Ljunghall.   

Abstract

Insulin-like growth factor I (IGF-I) is an important anabolic factor for osteoblasts in vitro. Low plasma levels of IGF-I have been observed in young men with osteoporosis. In the present study, we have studied bone mineral density (BMD) and the circulating levels of IGF-I and growth hormone (GH) in adults with acquired GH deficiency. BMD was determined by dual-energy x-ray absorptiometry in 17 men and 12 women (age 27-54 years). Spinal BMD was positively correlated with the plasma levels of IGF-I (r = 0.43, P = 0.019), with the median of GH values obtained by repeated sampling at night (r = 0.43, P = 0.0019), and with the peak of GH values during GHRH provocation test (r = 0.49, P = 0.039). The total BMD was positively related to plasma IGF-I and median of GH values, but not to peak GH by GHRH provocation. In a multiple regression analysis model, IGF-I, peak GH by GHRH provocation test and duration of GH deficiency explained 49% of the variation in spinal BMD. As compared to healthy controls, total, but not spinal, bone mass was lower in men with GH deficiency, but no clinical symptoms of osteoporosis were observed. The positive relationships between BMD and circulating IGF-I and other indices of GH secretion suggest that IGF-I has an endocrine effect on bone mass.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453131     DOI: 10.1111/j.1365-2796.1992.tb00613.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  16 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Growth hormone deficiency in the adult.

Authors:  M Doga; S Bonadonna; M Gola; G Mazziotti; A Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 3.  Skeletal effects of growth hormone and IGF-I in adults.

Authors:  R Marcus
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

4.  Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.

Authors:  V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli
Journal:  J Endocrinol Invest       Date:  2019-08-22       Impact factor: 4.256

5.  Serum insulin-like growth factor binding protein-1 levels and bone mineral density in older adults: the Rancho Bernardo Study.

Authors:  Simerjot K Jassal; Denise von Muhlen; Elizabeth Barrett-Connor; Clifford J Rosen
Journal:  Osteoporos Int       Date:  2005-08-09       Impact factor: 4.507

Review 6.  Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Authors:  Katarina T Borer
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

7.  Osteosarcopenia in Reproductive-Aged Women with Polycystic Ovary Syndrome: A Multicenter Case-Control Study.

Authors:  Maryam Kazemi; Brittany Y Jarrett; Stephen A Parry; Anna E Thalacker-Mercer; Kathleen M Hoeger; Steven D Spandorfer; Marla E Lujan
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

8.  Low bone mineral density in a growth hormone deficient (GHD) adolescent.

Authors:  Anna Capozzi; Silvia Della Casa; Barbara Altieri; Alfredo Pontecorvi
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 10.  Growth hormone replacement therapy for growth hormone-deficient adults.

Authors:  J Powrie; A Weissberger; P Sönksen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.